Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JINS HoldingsJNDOF +68.92%96 EBITDA Margin % is 16.39% as of Feb. 2026, which is 34% above its 10-year median of 12.22. GuruFocus rates JNDOF with a GF Score™ of 96/100 and a GF Value™ of $42.68. Among 817 Medical Devices & Instruments companies, JINS Holdings ranks better than 62.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. JINS Holdings's EBITDA for the
three
months ended in Feb. 2026 was $28.0 Mil. JINS Holdings's Revenue for the
three
months ended in Feb. 2026 was $171.0 Mil. Therefore, JINS Holdings's EBITDA margin for the quarter that ended in Feb. 2026 was 16.39%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JINS Holdings EBITDA Margin % Related Terms
JINS Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for JINS Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JNDOF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, JINS Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JINS Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JINS Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JINS Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JINS Holdings (JNDOF) has a EBITDA Margin % of 16.39% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JINS Holdings and its competitors. This is 34% above median its historical median of 12.22. Over the past decade, JINS Holdings' EBITDA Margin % has ranged from 7.78 to 15.15. According to the industry distribution chart, JINS Holdings ranks #306 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 37.5%.
Is JINS Holdings' EBITDA Margin % too high?
JINS Holdings' current EBITDA Margin % of 16.39% is 34% above median its 10-year median of 12.22. Over the past 10 years, this metric has ranged from a low of 7.78 to a high of 15.15. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. JINS Holdings' value of 16.39% is 120.3% above this industry median. Based on the distribution chart, JINS Holdings ranks #306 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, JINS Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does JINS Holdings' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JINS Holdings ranks #306 out of 817 companies for EBITDA Margin %. This puts JINS Holdings in the upper half of its industry. The industry median EBITDA Margin % is 7.44. JINS Holdings' value of 16.39% is 120.3% above this benchmark. Historically, JINS Holdings' own EBITDA Margin % has ranged from 7.78 to 15.15 over the past decade. While the company's 10-year median is 12.22 vs. the industry median of 7.44, JINS Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JINS Holdings's current EBITDA Margin % of 16.39% is 120.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JINS Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JINS Holdings's current EBITDA Margin % is 16.39%, which is 34% above median its own 10-year median of 12.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JINS Holdings stock overvalued right now?
JINS Holdings (JNDOF) has a current EBITDA Margin % of 16.39%. The stock's GF Value™ is $42.68, compared to a current price of $38.43 — trading 10% below its estimated fair value. The current EBITDA Margin % is 16.39%, which is 34% above median its 10-year median of 12.22 and 120.3% above the Medical Devices & Instruments industry median of 7.44. JINS Holdings' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JINS Holdings (JNDOF), the current EBITDA Margin % is 16.39% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JINS Holdings (JNDOF) Overvalued in 2026?
Based on GuruFocus' analysis, JINS Holdings stock appears to be undervalued.
The current stock price of $38.43 is trading 10% below its estimated GF Value™ of $42.68.
Key valuation signals for JNDOF:
EBITDA Margin %: 16.39% (34% above median its 10-year median of 12.22)
GF Value™: $42.68 vs. price of $38.43 (10% below fair value)
Industry Position: 120.3% above the Medical Devices & Instruments median (#306 of 817)
No single metric tells the full story. See the JNDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JINS Holdings Inc is an eyewear retailer that manufactures and sells private-label fashion eyeglasses and sunglasses. It offers prescription eyeglasses and nonprescription fashion or functional eyeglasses. Its inventory is on the shelves, and it charges flat rates with generally no additional charges or options for lens features. Jin has more than 300 stores in Japan as well as locations in China, Taiwan, and the United States. Stores are typically located in high-traffic areas such as shopping centers, malls, and train stations.
96GF Score
Get the complete analysis for JNDOF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNDOF has been successfully added to your 
